Steady progress as Keytruda gets set to top $20 billion in 2022

26 January 2023

Leading checkpoint blocker Keytruda (pembrolizumab) has offered a mixed bag of outcomes for people with two different types of cancer.

As part of its broad clinical trial program, Merck & Co (NYSE: MRK) has been testing the therapy in the Phase III KEYNOTE-991 study in metastatic hormone-sensitive prostate cancer and the Phase III KEYNOTE-966 study in first-line biliary tract cancer.

While results from a planned interim analysis of the former show the trial missed its primary efficacy endpoints, a more positive note was sounded from the latter study, which met its primary endpoint of overall survival (OS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK